BridgeBio Pharma, Inc. (BBIO) Stock

BridgeBio Pharma, Inc. is at the forefront of discovering, developing, and delivering innovative therapies for a spectrum of genetic diseases. The company boasts a robust pipeline comprising 30 programs that span from early discovery stages to advanced phases of development. Among its notable advancements are AG10 and BBP-265, both small molecule stabilizers of transthyretin (TTR), currently undergoing Phase 3 clinical trials for the treatment of TTR amyloidosis-cardiomyopathy (ATTR-CM). Additionally, BBP-831, a selective inhibitor targeting FGFR1-3, is in Phase 2 clinical trials aimed at treating achondroplasia in pediatric patients. Furthermore, BBP-631, an AAV5 gene transfer therapy, is in Phase 2 trials for congenital adrenal hyperplasia driven by 21-hydroxylase deficiency (21OHD).

The company's diverse portfolio extends to include Encaleret, a small molecule antagonist of the calcium sensing receptor (CaSR), currently undergoing Phase 2 proof-of-concept trials for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BridgeBio Pharma, Inc. is also advancing BBP-711 for the treatment of hyperoxaluria and patients prone to recurrent kidney stones. Beyond these initiatives, BridgeBio Pharma, Inc. is actively developing therapies for Mendelian disorders, oncology, and gene therapy applications, underscoring its commitment to addressing unmet medical needs across various disease categories.

Founded in 2015 and headquartered in Palo Alto, California, BridgeBio Pharma, Inc. operates at the intersection of scientific innovation and clinical advancement. The company's strategic partnerships, including licensing and collaboration agreements with prominent institutions such as Leland Stanford Junior University and The Regents of the University of California, highlight its collaborative approach to accelerating therapeutic development.

BridgeBio Pharma, Inc.'s pioneering spirit is driving transformative change in the biopharmaceutical industry, with a focus on translating cutting-edge research into effective treatments that improve patient outcomes worldwide. Positioned in the heart of Silicon Valley, the company leverages its proximity to innovation and talent to propel its mission of advancing precision medicine and reshaping the future of healthcare.